LNTH Lantheus Holdings Inc

Lantheus to Present at the 2025 Truist Securities MedTech Conference

Lantheus to Present at the 2025 Truist Securities MedTech Conference

BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17.

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Sweden and Switzerland, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

Melissa Downs

Executive Director, External Communications

646-975-2533



EN
10/06/2025

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Presentations to be featured at the 2025 Society of...

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking...

June 11, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at the 2025 Truist Securities MedTech Conference

Lantheus to Present at the 2025 Truist Securities MedTech Conference BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17. To access a live webcast of the presentation, please visit the Investors section of the Company’s website at . A re...

June 10, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare...

Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 BEDFORD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 at 2:40 p.m. ET on Tuesday, June 10. To access a live webcast of the presentation, please visit the Investors sectio...

June 3, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Reports First Quarter 2025 Financial Results and Provides Bus...

Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture...

May 7, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Sale of SPECT Business to SHINE Technologies

Lantheus Announces Sale of SPECT Business to SHINE Technologies Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced a definitive agreement to sell its single photo...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch